Gland Pharma Limited (GLAND) — Cash Flow Quality Index
Gland Pharma Limited (GLAND) has a Cash Flow Quality Index of 1.49x as of September 2025. Operating cash flow of Rs5.93 Billion exceeds net income of Rs3.99 Billion, indicating high earnings quality where cash backs reported profits. Explore Gland Pharma Limited cash conversion from operations to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Gland Pharma Limited Cash Flow Quality Index (2017–2026)
Historical Cash Flow Quality Index for Gland Pharma Limited across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Gland Pharma Limited total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Gland Pharma Limited (2017–2026)
Year-by-year earnings quality comparison for Gland Pharma Limited. For live market cap and the full company financial profile, see GLAND market cap overview.
| Year | Quality Index | Operating CF (INR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2026 | 1.20x | Rs12.31 Billion | Rs10.27 Billion | ▼ -8.5% |
| 2025 | 1.31x | Rs9.15 Billion | Rs6.99 Billion | ▲ +1.5% |
| 2024 | 1.29x | Rs9.97 Billion | Rs7.72 Billion | ▲ +273.9% |
| 2023 | 0.35x | Rs3.64 Billion | Rs10.55 Billion | ▼ -29.4% |
| 2022 | 0.49x | Rs7.91 Billion | Rs16.19 Billion | ▲ +7.8% |
| 2021 | 0.45x | Rs6.05 Billion | Rs13.35 Billion | ▼ -35.8% |
| 2020 | 0.71x | Rs7.01 Billion | Rs9.93 Billion | ▲ +161.5% |
| 2019 | 0.27x | Rs1.85 Billion | Rs6.86 Billion | ▼ -33.0% |
| 2018 | 0.40x | Rs2.02 Billion | Rs5.01 Billion | ▼ -65.0% |
| 2017 | 1.15x | Rs4.76 Billion | Rs4.14 Billion | — |